Head-to-head evidence
Furosemide (subcutaneous, SQ Innovation) vs Torsemide (Soaanz)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Heart Failure
Shared mechanism: NKCC2 · full Heart Failure pipeline
Furosemide (subcutaneous, SQ Innovation) · Lasix ONYU
Marketed by SQ Innovation
NCT02579057 · Phase 2/3 · completed
Patients were randomized to subcutaneous or intravenous furosemide, but the study was open-label with no blinding, and no formal statistical comparison of urine output between the two routes was reported, so this is limited evidence rather than a clear efficacy demonstration.
Next expected readout: November 2026 · NCT07008365 (registry estimate)
Torsemide (Soaanz)
Marketed by Sarfez Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Furosemide (subcutaneous, SQ Innovation)'s landscape · Torsemide (Soaanz)'s landscape